Author

Xavier Hebuterne 1

1 Archet 2 Hospital

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Raja Atreya, Laurent Peyrin–Biroulet, Andrii Klymenko, Monica Augustyn, Igor Bakulin, Dusan Slankamenac, Pal Miheller, Antonio Gasbarrini, Xavier Hebuterne, Karin Arnesson, Thomas Knittel, Jan Kowalski, Markus F. Neurath, William Sandborn, Walter Reinisch

COMPARISON OF EFFICACY AND TOLERANCE OF TWO MAINTENANCE REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE.

Jerome Filippi, Daniela Agrefilo, Eric Fontas, Xavier Hebuterne

CT-Scout<sup>TM</sup> platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: a multicenter prospective observational comparative study involving 134 sites and 644 patients in 6 countries

Yoram Bouhnik, Xavier Hebuterne, Raith Mrad, Aurelien Amiot, Carmen Stefanescu, David Laharie, Xavier Roblin, A. Boureille, Norman Sabbah, Laurent Peyrin-Biroulet

Effectiveness and safety of endoscopic balloon dilation of colorectal strictures in Crohn's disease

Marion Tilmant, Mélanie Serrero, Florian Poullenot, Guillaume Bouguen, Benjamin Pariente, Romain Altwegg, Paul Basile, Jerome Filippi, Pierre Vanelslander, Anthony Buisson, Lucine Vuitton, Ariadne Desjeux, David Laharie, Eric Le Balc'h, Maria Nachury, Lucile Boivineau, Guillaume Savoye, Xavier Hebuterne, Laurent Poincloux

EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

Mathurin Fumery, Antoine Defrance, Xavier Roblin, Carmen Stefanescu, Bénédicte Caron, Xavier Hebuterne, Romain Altwegg, Catherine Leberre, Maria Nachury, Antoine Meyer, Philippe Ah Soune, Cyrielle Gilletta De Saint Joseph, Nicolas DUVEAU, Mathieu Uzzan, Amelie Biron, David Laharie, Stephane NANCEY, My-Linh Tran-Minh, Ludo

EFFICACY OF ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE AND SYMPTOMATIC SMALL BOWEL STRICTURE: A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL COHORT STUDY

Yoram Bouhnik, David Laharie, Carmen Stefanescu, Xavier Hebuterne, Vered Abitbol, Maria Nachury, Arnaud Bourreille, Laurence Picon, Anne Bourrier, Matthieu Allez, Laurent Peyrin-Biroulet, Jacques Moreau, Guillaume Savoye, Mathurin Fumery, Stéphane Nancey, Xavier Roblin, Romain Altwegg, Guillaume Bouguen, Gilles Bommelaer;

EFFICACY AND SAFETY OF GOLIMUMAB IN CROHN’S DISEASE : A FRENCH NATIONAL RETROSPECTIVE STUDY

Chloé Martineau, Bernard Flourie, Pauline Wils, Thibaut Vaysse, Romain Altwegg, Anthony Buisson, Aurelien Amiot, Guillaume Pineton de Chambrun, Vered Abitbol, Mathurin Fumery, Xavier Hebuterne, Stéphanie Viennot, David Laharie, Laurent Beaugerie, Stéphane Nancey, Harry Sokol

Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: combined results from 382 subjects in the phase 2b study U-ACHIEVE

Peter D.R. Higgins, Xavier Hebuterne, Jesse Siffledeen, Wen Zhou, Fabio Cataldi, Wangang Xie, Ana P. Lacerda, Silvio Danese

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Severine Vermeire, Silvio Danese, Wen Zhou, Xuan Yao, Dapo Ilo, G Levy, Xavier Hebuterne, James O. Lindsay, Yuri Sanchez Gonzalez, Peter D.R. Higgins, Jean-Frédéric Colombel, Remo Panaccione

Item 1 - 10 / 55
1
2 3 4 5 6